Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

Atea has struggled to demonstrate bemnifosbuvir’s COVID potential in the past, including in a phase 2 trial back in the midst ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Merck stock was falling. Rival Summit Therapeutics said its cancer drug Ivonescimab reduced the risk of disease progression ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Distribution of the self-amplifying mRNA vaccine Kostaive is set to align with a planned October 2024 Covid-19 vaccination ...

EMD Serono Inc., Merck KGaA’s North American drug development business ... Vertex Pharmaceuticals Inc. recently extended its ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been ...

RAHWAY, N.J., September 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s ...